Clinical Trials for Other Solid Tumor

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adults with advanced or metastatic solid tumors who will receive Lattice Radiation Therapy (LRT) as an experimental treatment, with a focus on evaluating its effectiveness compared to standard stereotactic body radiation therapy (SBRT) in controlling extra-cranial soft tissue metastases and influencing immune cell infiltration.

ClinicalTrials.gov ID: NCT05837767

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial targets patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have an ECOG performance status of 0-1 and no prior systemic treatment, evaluating the effectiveness of Tumor Treating Fields (TTFields), which disrupt cancer cell division, in combination with pembrolizumab, an immune checkpoint inhibitor, and platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT06216301

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced solid malignancies, evaluating the safety and efficacy of the PARP inhibitor AZD5305, both alone and combined with agents like Paclitaxel and Trastuzumab Deruxtecan, showing promising response rates and reduced hematologic toxicity.

ClinicalTrials.gov ID: NCT04644068

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with metastatic EGFR-mutant non-small cell lung cancer, investigating the combination of osimertinib, an EGFR tyrosine kinase inhibitor, and tegavivint, a Wnt/β-catenin pathway inhibitor, to assess safety, tolerability, and preliminary efficacy.

ClinicalTrials.gov ID: NCT04780568

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with advanced or metastatic HR+/HER2-negative breast cancer, CRPC, and NSCLC who have progressed after prior therapies, and investigates PF-07248144, a KAT6A/B inhibitor, both as a monotherapy and in combination with fulvestrant, palbociclib, letrozole, or PF-07220060, a CDK4-specific inhibitor.

ClinicalTrials.gov ID: NCT04606446

Phase II Randomized Controlled Trial of Biologically Guided Stereotactic Body Radiation Therapy in Oligoprogressive Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial involves adult patients with non-small cell lung cancer, melanoma, or renal cell carcinoma with 1-5 oligoprogressive sites, treated with either standard SBRT or PET-guided SBRT that uses a biologically adaptive strategy to escalate radiation doses based on PET imaging. These patients are receiving or have received systemic therapy with checkpoint inhibitors, and the trial aims to assess the feasibility and safety of this adaptive approach.

ClinicalTrials.gov ID: NCT05830058

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Prodrug Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the safety and efficacy of AVA6000, a fibroblast activation protein-alpha (FAP)-activated prodrug of doxorubicin, in adult patients with various locally advanced or metastatic solid tumors who have not responded to standard treatments. It involves dose-escalation and expansion phases to optimize dosing and assess therapeutic activity.

ClinicalTrials.gov ID: NCT04969835

Pilot Study of a Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with stage IV ALK-positive non-small cell lung cancer who have stable disease on ALK inhibitors, testing a peptide vaccine designed to stimulate T-cell responses to prevent resistance to ALK-targeted therapies.

ClinicalTrials.gov ID: NCT05950139

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates the safety and potential efficacy of ABBV-514, an afucosylated monoclonal antibody targeting CCR8, as monotherapy and in combination with Budigalimab, a PD-1 inhibitor, in adults with advanced NSCLC, HNSCC, and other solid tumors resistant or intolerant to standard treatments.

ClinicalTrials.gov ID: NCT05005403

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the efficacy of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (FSRS) in patients aged 18 or older with intact brain metastases from specified solid tumors, including non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma, and gastrointestinal cancer, who have a Karnofsky performance status of 60 or above and up to eight brain metastases.

ClinicalTrials.gov ID: NCT06500455